FGD1 mutations result in Faciogenital Dysplasia (FGDY), an X-linked human disease that affects skeletal formation and embryonic morphogenesis. FGD1 and Fgd1, the mouse FGD1 ortholog, encode guanine nucleotide exchange factors (GEF) that specifically activate Cdc42, a Rho GTPase that controls the organization of the actin cytoskeleton. To further understand FGD1/Fgd1 signaling and begin to elucidate the molecular pathophysiology of FGDY, we demonstrate that Fgd1 directly interacts with cortactin and mouse actin-binding protein 1 (mAbp1), actin-binding proteins that regulate actin polymerization through the Arp2/3 complex. In yeast two-hybrid studies, cortactin and mAbp1 Src homology 3 (SH3) domains interact with a single Fgd1 SH3-binding domain (SH3-BD), and biochemical studies show that the Fgd1 SH3-BD directly binds to cortactin and mAbp1 in vitro. Immunoprecipitation studies show that Fgd1 interacts with cortactin and mAbp1 in vivo and that Fgd1 SH3-BD mutations disrupt binding. Immunocytochemical studies show that Fgd1 colocalizes with cortactin and mAbp1 in lamellipodia and membrane ruffles, and that Fgd1 subcellular targeting is dynamic. By using truncated cortactin proteins, immunocytochemical studies show that the cortactin SH3 domain targets Fgd1 to the subcortical actin cytoskeleton, and that abnormal Fgd1 localization results in actin cytoskeletal abnormalities and significant changes in cell shape and viability. Thus, this study provides novel in vitro and in vivo evidence that Fgd1 specifically and directly interacts with cortactin and mAbp1, and that these interactions play an important role in regulating the actin cytoskeleton and, subsequently, cell shape.
INTRODUCTION
FGD1 is implicated as a critical participant in mammalian development because mutations in this gene result in the disease Faciogenital Dysplasia (FGDY; Aarskog syndrome), a skeletal dysplasia and multiple congenital anomaly syndrome (1, 2) . Most FGD1 mutations are predicted null alleles; thus the X-linked recessive phenotype appears to be due to the absence of the gene product in affected males (2) . FGD1 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the Rho (Ras homology) GTPase Cdc42 (3, 4) . Cdc42 plays a critical role in regulating actin polymerization, vesicular transport, the cell cycle and cell polarity (5) . By activating Cdc42, FGD1 potently stimulates reorganization of the actin cytoskeleton and the formation of filopodia, long cross-linked parallel actin filaments (3) . Through Cdc42, FGD1 also stimulates the passage of cells through the G1 phase of the cell cycle (6) , promotes cell transformation (7) and activates c-Jun N-terminal kinase (3, 4) . During embryogenesis, the mouse FGD1 ortholog, Fgd1 (960 residues, >95% identical to human FGD1), exhibits a limited pattern of expression that is largely restricted to regions of incipient and active ossification including skeletal elements involved in the FGDY phenotype (8) . Together, these data indicate that Fgd1/Cdc42 signaling plays an important role in mammalian embryonic development and skeletal formation (2) .
Rho guanine nucleotide exchange factor (RhoGEF) proteins play critical roles in regulating Rho GTPase activity (5) . RhoGEFs activate Rho GTPases by catalyzing the exchange of bound GDP for GTP, thereby inducing a conformational change in the GTP-bound GTPase that allows it to interact with downstream effector proteins (9) . Data indicate that RhoGEF activation is a multi-step process that proceeds sequentially from RhoGEF recruitment to a specific subcellular region to RhoGEF activation (10) . In addition to a GEF (or Dbl homology, DH) domain, most RhoGEF proteins contain a variety of different signaling domains (9) . Mouse (and human) Fgd1 is composed of several different signaling domains including a proline-rich N-terminal region, adjacent DH and pleckstrin homology (PH) domains, a FYVE domain, and a second C-terminal PH (PH2) domain (1, 11) . Thus, like other RhoGEFs, Fgd1 contains several putative signaling domains (2) . Biochemical and immunocytochemical studies localize endogenous and overexpressed Fgd1 protein to the cell cortex, cytoplasm, and Golgi complex (12) . Data also indicate that, as part of their targeted activation, RhoGEFs interact with different proteins to form signaling complexes (13) . Thus, these data suggest that Fgd1 signaling domains might be involved in targeting Fgd1 to different subcellular regions to regulate Cdc42 activation.
To further understand Fgd1 signaling and begin to elucidate the molecular pathophysiology of Faciogenital Dysplasia, we have identified two distinct but related Fgd1-interacting proteins, cortactin and mouse actin-binding protein (mAbp1). Yeast two-hybrid analyses and binding studies show that a single Fgd1 SH3-binding domain (SH3-BD) directly interacts with cortactin and mAbp1 SH3 domains. Immunocytochemical studies show that Fgd1 colocalizes with both cortactin and mAbp1 in the subcortical actin cytoskeleton. Studies also indicate that the cortactin SH3 domain targets Fgd1 to the cell cortex, and that abnormal Fgd1 targeting induces changes in cell shape and viability. These data strongly suggest that Fgd1 plays a key role in regulating the actin cytoskeleton: by binding to cortactin and mAbp1, Fgd1 is targeted to the dynamic cortical actin cytoskeleton; by activating Cdc42, Fgd1 indirectly activates N-WASP to stimulate Arp2/3-directed actin polymerization and filopodia formation.
RESULTS

Fgd1 interacts with cortactin and mAbp1 in yeast two-hybrid studies
Yeast two-hybrid analyses were performed to identify Fgd1-interacting proteins. For this purpose, L-F1, a LexA-Fgd1 fusion bait plasmid encoding full-length Fgd1, was used to screen a mouse osteoblast two-hybrid cDNA library. Studies showed that 22 independently isolated cDNA clones displayed L-F1-dependent yeast reporter gene transactivation. Sequence analyses showed that these cDNA clones fell into two distinct classes: (i) 12 clones encoded mouse cortactin (14) , and (ii) 10 clones encoded mouse actin-binding protein (mAbp1; SH3P7) (15, 16) . Analyses showed that cortactin and mAbp1 shared similar structural domains ( Fig. 1A and B) ; both proteins contained (in order) N-terminal actin-binding domains, a-helical regions, proline-serine-threonine (PST)-rich regions, and C-terminal Src homology 3 (SH3) domains (16, 17) . Thus, these data showed that, in the yeast two-hybrid system, Fgd1 interacts with two different but related actinbinding proteins.
Since all isolated cDNAs encoded a SH3 domain (Fig. 1A  and B) , data suggested that cortactin and mAbp1 interacted with a Fgd1 SH3 binding domain (SH3-BD). Sequence analyses showed that the cortactin and mAbp1 SH3 domains were highly related with 82% similarity and 67% identity (Fig. 1C) ; cortactin and mAbp1 also bind to identical SH3-BD ligands (18, 19) . As shown in Figure 2A and B, L-F4, a bait plasmid containing part of the Fgd1 N-terminal proline-rich domain (PRD) interacted with cortactin and mAbp1 SH3 domains in the yeast two-hybrid system to transactivate yeast HIS3 and LacZ reporter genes. By contrast, Fgd1 bait plasmids containing the DH and PH domains (L-F2) and the FYVE and PH2 domains (L-F3) failed to interact. Synthetic peptides corresponding to individual Fgd1 N-terminal polyproline sequences were used to generate bait plasmids to define the specific Fgd1 SH3-BD region. Inspection of the Fgd1 PRD showed that it contained at least two putative SH3-BDs: codons 158-168 encoded a PKPQVPPKP sequence that was similar to a predicted cortactin SH3-BD consensus sequence (Fig. 2C) ; residues 178-187 encoded a EPIPPPPSRP sequence that was similar to the predicted c-Abl SH3-BD consensus sequence (1). L-F6, a bait plasmid containing the first putative Fgd1 SH3-BD, interacted with both cortactin and mAbp1 SH3 domains ( Fig. 2A and B) , but a bait plasmid containing the second putative SH3-BD (L-F5) failed to interact. In addition, bait plasmids containing mutations predicted to disrupt the first SH3-BD (L-F7 and L-F8; Fig. 2A and B) failed to interact. By contrast, bait plasmids containing missense mutations flanking the critical SH3-BD residues interacted with the cortactin and mAbp1 SH3 domains (data not shown). These data suggested that a single Fgd1 SH3-BD interacted with the cortactin and mAbp1 SH3 domains.
The Fgd1 SH3-BD directly binds to cortactin and mAbp1 SH3 domains in vitro Binding studies were performed to determine if cortactin and mAbp1 SH3 domains bound directly to the Fgd1 SH3-BD (Fig. 3A) . A radiolabeled GST-fusion protein containing the mAbp1 SH3 domain (GST-AbpSH3) selectively bound to Fgd1 GST-fusion proteins containing either long (GST-F4) or short (GST-F6) fragments spanning the Fgd1 SH3-BD. By contrast, GST-AbpSH3 failed to bind to GST-F5, a GST-fusion protein containing a second putative Fgd1 SH3-BD, and bound to GST-F8, a GST-fusion protein containing a mutant Fgd1 SH3-BD, with much less affinity. A labeled GST-fusion protein containing the cortactin SH3 domain (GST-CortSH3) yielded a similar binding pattern (Fig. 3A) . Labeled mAbp1 and cortactin SH3 GST-fusion proteins failed to bind to control GST protein, and labeled GST protein failed to bind to any of the proteins (Fig. 3A) ; thus, these analyses indicated that the observed interactions were specific.
The specificity of these interactions was further analyzed by incubating a labeled GST-fusion protein containing Fgd1 SH3-BD (GST-F6) with membranes containing mAbp1, cortactin and Grb2 SH3 GST-fusion proteins. Labeled GST-F6 protein selectively bound to both mAbp1 and cortactin SH3 GST-fusion proteins but failed to bind to either of the two Grb2 SH3 domains (Fig. 3B) . Competition-binding experiments were also performed. In these studies, GST-fusion proteins containing either a wild-type (GST-F6) or mutated (GST-F8) Fgd1 SH3-BD were assayed for the ability to competitively interfere with the binding of labeled GST-F6 to mAbp1 and cortactin SH3 GST-fusion proteins. As shown in Figure 3C , the binding of labeled Fgd1 SH3-BD GST-fusion protein was reduced in a dose-dependent manner with increasing concentrations of non-labeled GST-F6 in the nanomolar range (30-300 nM). In contrast, 300 nM of mutant GST-F8 protein failed to block Fgd1-mAbp1 and Fgd1-cortactin binding. These data indicated that in vitro binding between Fgd1 SH3-BD and cortactin and mAbp1 SH3 domains was direct and specific.
Fgd1 colocalizes with cortactin and mAbp1 in the membrane ruffles of stimulated cells
Since our data showed that Fgd1 physically interacted with cortactin and mAbp1, GFP-tagged Fgd1, and Flag-tagged cortactin and mAbp1 proteins were transiently expressed in COS-7 cells to determine if protein distributions were consistent with direct interactions. We previously showed that, in these cells, transiently overexpressed Fgd1 proteins demonstrated a subcellular distribution indistinguishable from that observed in cells that endogenously express Fgd1 (12) . When expressed in quiescent serum-deprived cells, mAbp1 and cortactin proteins were primarily distributed in the cytoplasm; relatively minor amounts of the Flag-tagged proteins were localized at the cell cortex (Fig. 4A) . In contrast, upon PDGF stimulation, Flag-mAbp1 and Flag-cortactin were rapidly redistributed to lamellipodia, findings consistent with previous studies (16, 25) . GFP-tagged Fgd1 displayed a dynamic subcellular distribution similar to that observed with cortactin and mAbp1 (Fig. 4A) . In quiescent cells, GFP-Fgd1 was primarily distributed in the cytoplasm and Golgi complex with little protein present at the cell cortex. By contrast, in stimulated cells, a significant amount of GFP-Fgd1 was redistributed to the cell cortex. Cotransfection studies were performed to determine if Fgd1 colocalized with cortactin, and mAbp1 (Fig. 4B ). When coexpressed with Flag-mAbp1 in stimulated cells, in addition to being present in the cytoplasm and Golgi complex, like Flag-mAbp1, GFP-Fgd1 was targeted to the leading edge of cells in lamellipodia. Similarly, when GFP-Fgd1 was coexpressed with Flag-cortactin, these proteins were primarily localized in cortical ruffles at the leading edge of motile cells (Fig. 4B) . These data showed that the subcellular distribution of Fgd1 was dynamic and that Fgd1 colocalized with both cortactin and mAbp1 in the cell cortex.
Fgd1 specifically interacts with overexpressed cortactin and mAbp1 in vivo
Previously, we showed that endogenous Fgd1 is present in low concentrations and prone to rapid proteolytic digestion (12) . Thus, to determine whether Fgd1 interacted with mAbp1 and cortactin in vivo, epitope-tagged proteins were expressed in COS-7 cells, and Flag-tagged cortactin or Flag-tagged mAbp1 was immunoprecipitated with anti-Flag antibody. As shown in Figure 5 , when Flag-Abp and GFP-tagged Fgd1 (GFP-F1) were coexpressed in cells, anti-Flag antibody coimmunoprecipitated GFP-F1 with Flag-Abp. Control studies showed that immunoprecipitation was dependent upon the expression of both FlagAbp and GFP-F1. The specificity of this interaction was analyzed by expressing Flag-Abp with a full-length GFPtagged Fgd1 protein containing P159A and P162A mutations in the SH3-BD (GFP-DF1); yeast two-hybrid analyses and in vitro binding studies showed that these mutations interfered with cortactin and mAbp1 binding (see above). Despite equivalent expression of GFP-F1 and GFP-DF1 proteins, when coexpressed with Flag-Abp, anti-Flag antibody failed to coimmunopreciptate GFP-DF1 protein with Flag-Abp ( 
Truncated cortactin redirects Fgd1 targeting
Our data showed that the distribution of Fgd1 was dynamic, and that Fgd1 colocalized with cortactin at the cell cortex; thus, experiments were performed to examine whether Fgd1-cortactin interactions affected Fgd1 localization. For this purpose, we examined whether the expression of truncated cortactin proteins lacking localization domains altered Fgd1 targeting (Fig. 6) ; the results of these experiments are summarized in Table 1 . Two different truncated myc-tagged cortactin proteins were used in these studies: myc-CterCort (residues 350-546) and mycCortSH3 (residues 491-546); both tagged cortactin proteins lack the N-terminal actin-binding regions and display a cytoplasmic and perinuclear distribution (17) . When coexpressed in cells, in addition to being distributed in the cytoplasm and perinuclear region, GFP-tagged Fgd1 (GFP-F1) and Flag-tagged full-length cortactin (Flag-Cort) colocalized with phalloidin-stained actin filaments at the cell cortex in large lamellipodia in motile cells (Fig. 6A) . In contrast, a markedly different protein distribution was observed in cells coexpressing GFP-F1 and the truncated cortactin protein, myc-CterCort (Fig. 6B ). Compared to GFP-F1/ Flag-Cort-expressing cells, cells coexpressing GFP-F1 and mycCterCort were significantly less motile. In these cells, GFP-F1 and myc-CterCort proteins were generally absent from the cell cortex; instead, these proteins colocalized in the cytoplasm and perinuclear region with actin aggregates. To confirm these studies, additional experiments were performed with cells coexpressing GFP-F1 and a second truncated cortactin protein, myc-CortSH3 (Fig. 6C) . Again, like the GFP-F1/myc-CterCortexpressing cells, cells coexpressing GFP-F1 and myc-CortSH3 displayed significantly reduced motility. In these cells, mycCortSH3 and GFP-F1 colocalized with the actin aggregates in the perinuclear region but were notably absent from the cell cortex. These cells also displayed a strikingly unusual phenotype with an unusual actin cytoskeleton and large perinuclear F-actin aggregates. Since GFP-F1 colocalized with these unusual actin structures, these data suggested that misdirected Fgd1 played a role in their formation. To address this question, we studied cells coexpressing full-length Flag-Cort and GFP-FDPRD, a GFPtagged Fgd1 protein lacking the N-terminal PRD; GFP-FDPRD is not distributed to the cell cortex (12) . When coexpressed in cells, GFP-FDPRD and Flag-Cort appeared to be significantly toxic, and expression was limited to a small number of nonmotile cells that expressed low levels of GFP-FDPRD (Fig. 6D) .
In these cells, Flag-Cort was present at the cell cortex; in contrast, GFP-FDPRD colocalized with F-actin aggregates in the perinuclear region and was notably absent from the cell cortex (Fig. 6D) . Together, these data demonstrated that Fgd1 interacted with truncated cortactin proteins in vivo, and that, in the absence of actin-binding domains, these truncated proteins targeted Fgd1 to the cytoplasm and perinuclear region, away from the subcortical actin cytoskeleton. These data also suggested that misdirected Fgd1 resulted in an altered actin cytoskeleton.
Altered Fgd1 targeting affects the actin cytoskeleton
Additional studies were performed to further characterize the consequences of aberrant Fgd1 targeting (Fig. 7) . For this purpose, GFP-FDPRD was expressed to block targeting to the cell cortex and cells were examined shortly after transfection to minimize the effects of cell toxicity; the results of these analyses are summarized in Table 1 . COS-7 cells expressing control GFP-F1 protein displayed a normal polarized motile phenotype and a significant proportion of GFP-F1 was present at the cell cortex at the leading edge (Fig. 7A) . Similar results were obtained with several different mammalian cells including mouse osteoblast MC3T3-E1 cells and mouse fibroblast Swiss 3T3 and NIH 3T3 cells (data not shown). In contrast, cells expressing GFP-FDPRD displayed significantly reduced motility and an unusual morphology characterized by an aberrant actin cytoskeleton (Fig. 7B-D) . In expressing cells, GFP-FDPRD was distributed in the cytoplasm and perinuclear region; regardless of the level of expression, GFP-FDPRD was notably absent from the cell cortex. Phalloidin staining showed that, like GFP-F1/CortSH3-expressing cells (Fig. 6C) , GFP-FDPRD-expressing cells displayed an unusual actin cytoskeleton and contained large perinuclear actin aggregates. Cells expressing relatively small amounts of GFP-FDPRD typically contained unusual thick cords of actin in the cytoplasm and at the cell cortex (Fig. 7B) . Cells expressing relatively more GFP-FDPRD displayed large cytoplasmic polyhedral rings of F-actin ( Fig. 7C and D) . These rings appeared to delimit GFP-FDPRD distribution; GFP-FDPRD was primarily distributed within the rings and excluded from the cell cortex ( Fig. 7C-E) . Similar abnormalities were observed in NIH 3T3 and Swiss 3T3 fibroblasts (data not shown). These data showed that aberrant Fgd1 targeting resulted in a complex cellular phenotype that was characterized by decreased cell motility, reduced cell viability, and a markedly altered actin cytoskeleton with perinuclear actin aggregates, unusual actin cords, and cytoplasmic polyhedral actin rings. Together, these data indicated that anomalous Fgd1 targeting results in altered actin cytoskeletal organization and, consequently, an abnormal cell phenotype.
DISCUSSION
In this study, we demonstrate that Fgd1, a Cdc42-specific GEF involved in mammalian embryonic development, directly interacts with cortactin and mAbp1, actin-binding proteins that regulate the actin polymerization through the Arp2/3 complex. These data show that Fgd1 binds to the SH3 domains of cortactin and mAbp1 by a single N-terminal SH3-BD to target Fgd1 to the subcortical actin cytoskeleton. Several lines of evidence demonstrate that Fgd1 directly interacts with cortactin and mAbp1 in vitro and in vivo. Fgd1 interacts with cortactin and mAbp1 in yeast two-hybrid studies and mutations in the Fgd1 SH3-BD specifically disrupt these interactions. Biochemical analyses show that the Fgd1 SH3-BD binds directly to the cortactin and mAbp1 SH3 domains in vitro.
Immunocytochemical studies show that Fgd1 colocalizes with both cortactin and mAbp1 in lamellipodia and membrane ruffles. Although protein instability interfered with our ability to perform endogenous coimmunoprecipitation studies, coimmunoprecipitation analyses performed with expressed proteins indicate that Fgd1 interacts with cortactin and mAbp1 in vivo and that Fgd1 SH3-BD mutations block this binding. Furthermore, immunocytochemical studies with truncated epitope-tagged proteins show that Fgd1 interacts with the cortactin SH3 domain in living cells and that this interaction redirects Fgd1 subcellular targeting. These studies also show that altered Fgd1 localization results in an anomalous actin cytoskeleton and abnormal cell morphology. Thus, this study provides novel in vitro and in vivo evidence that Fgd1 specifically and directly interacts with cortactin and mAbp1, and that Fgd1 appears to act with these proteins to regulate the actin cytoskeleton, and subsequently, cell shape.
Signal transduction relies on specific protein-protein interactions to provide accurate protein recruitment and precise subcellular targeting. Our data indicate that, like cortactin and mAbp1, the subcellular distribution of Fgd1 is dynamic; these data show that Fgd1 is redistributed between the cytoplasm and the cell cortex in response to growth factor stimulation. The observation that constitutively and exogenously expressing cells display the same subcellular distribution of Fgd1 strongly suggests that this localization is accurate and biologically relevant (12) . These data also show that cortactin interacts with Fgd1 to precisely target it to particular regions of the subcortical actin cytoskeleton. Although it is formally possible that Fgd1 plays a role in cortactin (and mAbp1) subcellular targeting, the observation that truncated cortactin SH3 protein redirects Fgd1 away from the cell cortex indicates that cortactin plays a dominant role in Fgd1 targeting. Thus, these data strongly suggest that cortactin binds to Fgd1 in the cytoplasm and subsequently brings Fgd1 to the cell cortex. This hypothesis is consistent with the observation that cortactin and mAbp1 contain actin-binding domains that directly link to actin filaments (16, 17) , motifs not found in Fgd1. Data show that RhoGEF activation is a multi-step process that is typically initiated by protein translocation (10) . Cdc42, the Fgd1 substrate, has been localized to several subcellular regions including the plasma membrane (26) . Consequently, by being targeted to the cell cortex, Fgd1 is poised to activate Cdc42 signaling at the plasma membrane. Thus, these data strongly suggest that cortactin and mAbp1 play important roles in targeting Fgd1 to the subcortical actin cytoskeleton for activation.
Since these data indicate that mAbp1 and cortactin directly interact with Fgd1, it is reasonable to hypothesize that these proteins might be involved in related cellular processes. Abp1p, the Saccharomyces cerevisiae mAbp1 homolog, is targeted to cortical actin patches, structures that are concentrated at growing yeast cell surfaces (27) . In yeast, Abp1p overexpression results in a depolarized distribution of cortical actin and loss of spatially regulated cell growth (27) ; these data suggest that Abp1p is critical in regulating the actin cytoskeleton and cell polarity. Data also implicates Abp1p as playing a role in endocytosis; for example, Abp1p has a redundant function with Sla2p in endocytic trafficking (28) , and Abp1p interacts with proteins that function in endocytosis (29) . In mammals, mAbp1 interacts directly with dynamin (19), a GTPase that regulates the formation of endocytic vesicles. Cortactin binds to filamentous actin and is enriched in cell-matrix contact sites and the lamellipodia of cultured cells (17) . Since cortactin also binds to large scaffolding proteins, it is implicated in playing a role in assembling large protein complexes to regulate actin cytoskeletal organization (30) . Cortactin is also a proto-oncogene and its amplified expression results in increased cell invasiveness (31) . Cortactin is overexpressed in a variety of cancers including ovarian, bladder, breast and lung carcinomas and head and neck tumors (32) . As cortactin overexpression is associated with a poor prognosis for many of these cancers (33) , these data suggest that elevated cortactin expression directly contributes to tumor severity. Together, accumulated data indicates that mAbp1 and cortactin play critical roles in regulating cell polarity, endocytosis and actin cytoskeletal organization. Thus, by inference, these data suggest that Fgd1 might also play an important role in these or related processes. Since these processes are, in part, regulated by the GTPase Cdc42 (5), this contention is consistent with Fgd1 being a Cdc42-specific GEF (3, 4, 12) .
Actin polymerization is a dynamic process in which actin nucleation, polymerization and actin filament stabilization are tightly regulated. The determination that Fgd1 binds directly to cortactin and mAbp1 strongly suggests that, through these interactions, Fgd1 directly or indirectly regulates the actin cytoskeleton. As a Cdc42-specific GEF targeted to the cell cortex, Fgd1 activates Cdc42 to stimulate N-WASP and Arp2/3 complex activation. We previously showed that Fgd1 stimulates Cdc42-dependent filopodia formation (3, 12) , a process driven by N-WASP activation of the Arp2/3 complex (34). Thus, these data showed that, through Cdc42, Fgd1 regulates N-WASP stimulation and Arp2/3 activation. Our data also indicate that Fgd1 directly binds to cortactin and mAbp1 at the subcortical actin cytoskeleton. Cortactin and yeast Abp1 both enhance the ability of the Arp2/3 complex to form branched actin filaments (35) (36) (37) . Data also show that cortactin-binding proteins are capable of indirectly stimulating the Arp2/3 complex by binding cortactin in vitro (38) . Thus, it is reasonable to hypothesize that Fgd1 might interact with cortactin to regulate Arp2/3 complex activation. It has also been shown that cortactin and N-WASP act synergistically to stimulate the Arp2/3 complex (37) . Together, these data strongly suggest that, as a cortactin-binding Cdc42GEF, Fgd1 is poised to modulate Arp2/3 activity by regulating and/or interacting with both N-WASP and cortactin. Conversely, it is possible that cortactin and/or mAbp1 bind to Fgd1 to regulate GEF activity. Additional experiments will be necessary to fully characterize the consequences of these interactions.
Our data also indicate that abnormal Fgd1 targeting results in an aberrant actin cytoskeleton and altered cell shape. Two different approaches were used to misdirect Fgd1 targeting: Fgd1 was drawn away from the cell cortex by binding it to truncated cortactin proteins; and truncated Fgd1 was misdirected from the actin cytoskeleton by the removal of its N-terminal domain. Each experiment yielded similar results: by either means, abnormal Fgd1 targeting resulted in a variety of actin cytoskeletal abnormalities including perinuclear actin aggregates, unusual actin cables and perinuclear actin rings. The observation that either full-length or truncated Fgd1 protein induced similar abnormal cellular phenotypes suggests that actin cytoskeleton aberrations are the result of abnormal Fgd1 targeting, not altered Fgd1 activity. Previous studies have clearly demonstrated that overexpressed and/or misdirected cortactin, mAbp1, and WASP-like proteins all cause defects in actin organization and unusual cell phenotypes (16, 27, 39) . Although it is unclear as to whether this is a general characteristic of all Arp2/3-interacting proteins, these results suggest that the overexpression of these proteins causes mislocalization of the Arp2/3 complex and, consequently, an abnormal actin cytoskeleton (40) . Collectively, these results strongly suggest that Fgd1 is an important component in regulating the actin cytoskeleton and cell shape.
Based on these results, a clearer image of the role of Fgd1/ FGD1 in mammalian skeletal formation is beginning to emerge. Expressed in osteoblasts and localized to the subcortical actin cytoskeleton, this Cdc42 activator is poised to influence osteoblast cytoskeletal organization, cell polarity, and vesicular transport (12) , cellular processes critical to normal cellular function and differentiation. In S. cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster, and Caenorhabditis elegans, the loss of RhoGEF activity is functionally equivalent to the loss of the target Rho protein (41); thus, it is likely that a loss of FGD1 activity results in disrupted osteoblast Cdc42 signaling. Several lines of evidence indicate that Cdc42 signaling and actin cytoskeletal regulation play critical roles in the molecular biology of skeletogenesis. Data show that, like epithelial cells, osteoblasts display apicalbasolateral polarity and secrete extracellular matrix (ECM) molecules in a polarized fashion (42) . Transgenic mice (43) (44) (45) and in vitro biochemical studies (46, 47) show that, in part, the ECM regulates osteoblast growth and function. Rho GTPases play a critical role in mediating signals from the ECM to modify cellular proliferation, cytoskeletal organization and differentiation (5) . In particular, Cdc42 signaling plays a critical role in regulating integrin-dependent cellular adhesion and cytoskeletal organization (48) . In embryonic chick osteoblasts, an intact actin cytoskeleton is required for the regulated expression of ECM molecules in response to mechanical strain (49) . In addition, studies show that the actin cytoskeleton and the Rho signaling cascade are involved in the detection and response to fluid shear induced mechanical signaling in osteoblast-like cells (50) . Studies have also demonstrated that the actin cytoskeleton is critical for determining and maintaining bone cell shape (51). Although we cannot rule out the formal possibility the FGD1 may be involved in additional signaling pathways, taken together, these observations suggest that FGD1/Cdc42 signaling plays a role in regulating the osteoblast actin cytoskeleton and that Faciogenital Dysplasia is a disorder of the FGD1/Cdc42 signaling.
MATERIALS AND METHODS
Cell culture and transfections
Mouse osteoblast cell line MC3T3-E1 (52) was provided by Dr Franceschi (University of Michigan) and COS-7 cells were purchased (ATCC, Manassas, VA). Calvarial cells were isolated as described (8) . Cells were cultured as described (8, 12) . For transfections, cells were plated into six-well trays with coverslips. Cells were transfected with 2-5 mg DNA per well using Lipofectamine-PLUS as recommended by the supplier (Life Technologies, Grand Island, NY). Cells were analyzed 12-36 h after transfection. To study the effects of growth factor stimulation, transfected cells were first allowed to recover in Dulbecco's modified Eagle Medium (DMEM) containing 10% fetal calf serum for 3 h, washed four times with DMEM, serum-deprived for 16 h in DMEM containing 0.1% BSA (Sigma Chemical, St Louis, MO), and stimulated with PDGFb 10 ng/ml (Sigma Chemical) in DMEM for 15 min.
cDNA libraries, cDNA clones, and DNA constructs RNA was isolated from mouse calvarial and MC3T3-E1 cells as described (1) . Osteoblast-derived poly(A) þ mRNA and random and oligo-dT primers were used to construct a pGAD10 cDNA library (Clontech, Palo Alto, CA) for yeast two-hybrid analysis. PCR primers were used to amplify a fulllength mAbp1 cDNA clone; mouse Fgd1 and cortactin cDNA clones were previously described (11, 14) .
For yeast two-hybrid studies, LexA-Fgd1 fusion protein expression constructs encoding Fgd1 were generated by PCR amplification; these included L-F1 (codons 1-960), L-F2 (codons 335-707), L-F3 (codons 714-922) and L-F4 (codons 131-195). PCR amplification was used to generate GAL4 activation domain (pAD) fusion proteins: full-length cortactin (pAD-Cort) and mAbp1 (pAD-Abp), and C-terminal fusion proteins pAD-AbpSH3 (codons 318-433) and pAD-CortSH3 (codons 490-546). Synthetic oligonucleotides were used to generate LexA-Fgd1 expression constructs encoding short PRD Fgd1 peptides: L-F5 (codons 170-190), L-F6 (codons 147-169), L-F7 (codons 147-169 with a K164E mutation) and L-F8 (codons 147-169 with P159A and P162A mutations); these same synthetic oligonucleotides were cloned into a modified pGEX-2TK (Amersham Pharmacia Biotech, Piscataway, NJ) vector to generate glutathione S-transferase (GST)-Fgd1 fusion protein constructs GST-F4, GST-F5, GST-F6 and GST-F8, respectively. PCR amplification was used to generate GSTprotein fusion constructs for cortactin (GST-CortSH3; codons 490-546), mAbp1 (GST-AbpSH3; codons 318-433), and Grb2 (GST-Grb2; codons 2-217). PCR amplification was used to generate green fluorescent protein (GFP)-tagged Fgd1 expression constructs GFP-F1 (codons 1-960) and GFP-FDPRD (codons 359-922) as described (12) . Site-directed mutagenesis was used to generate GFP-DF1, a GFP-tagged Fgd1 expression construct containing a mutated SH3-BD (codons 1-960 with mutations P159A and P162A). PCR amplification and pCMVtag2 (Stratagene) vector were used to generate a Flag-tagged mAbp1 construct Flag-Abp (codons 1-433); Flag-and myctagged cortactin expression constructs Flag-Cort (codons 1-546), myc-CterCort (codons 350-546), and myc-CortSH3 (codons 491-546), were described (17) . All constructs were verified by DNA sequencing. Fusion protein expression was confirmed by western blot analysis.
Yeast two-hybrid analyses
Yeast two-hybrid analyses were performed as described (20) . S. cerevisiae reporter strain L40 cells containing plasmid L-F1 were transformed with the osteoblast-derived pGAD10 cDNA library. An estimated 10 Â 10 6 transformants were grown in synthetic media to select for His þ colonies; His þ colonies were assayed for b-galactosidase activity by filter assay as described (20) . Of 201 independent His þ colonies, 194 were also LacZ þ ; 48 of these colonies were randomly selected to determine the proportion of LexA-Fgd1-dependent His þ LacZ þ colonies. Mating assays were performed to identify library clones that transactivated the HIS3 and LacZ reporter genes in a bait-specific manner (20) ; 24 of 48 colonies strongly transactivated reporter genes with LexA-Fgd1 plasmid. Library plasmids were isolated by transforming HB101 Escherichia coli (Life Technologies) with total yeast DNA (20) ; 22 independent transactivating library plasmids were recovered.
Protein-binding analyses
GST-fusion protein constructs were transformed into E. coli strain BL21 bacteria (Amersham Pharmacia Biotech); fusion protein expression was induced with 0.1-0.4 mM isopropyl b-D-thiogalactoside (Amersham) for 2-3 h. GST-fusion proteins were purified from cell lysates on glutathione-agarose beads as described (53) . Protein expression was verified by immunoblot analysis; protein concentrations were determined by the Cu þ / bicinchoninic acid method (Micro-BCA Protein Assay, Pierce) with BSA serving as the standard. GST-fusion proteins were fractionated by SDS-PAGE and transferred to Immobilon-P membranes (Millipore, MA) membranes as described (8) . To perform in vitro protein-binding analyses, GST-fusion proteins (100 mg protein/reaction) were radiolabeled using protein kinase A (54) . To detect protein-protein interactions, blot overlays were performed essentially as described (55) . For competition experiments, in addition to the radiolabeled protein, membranes were also incubated with different concentrations of unlabeled GST-fusion protein (see Results).
Antibodies, immunoblotting and immunoprecipitation
For immunoprecipitation analyses, transfected COS-7 cells were lysed with protease inhibitor cocktail as described (12) . Cell homogenates were centrifuged at 10 000g for 30 min and clarified lysates (200 mg) were incubated with 50 ml of FLAG M2 affinity resin (Sigma Chemical) overnight at 4 C. Immune complexes were collected by centrifugation and washed with lysis buffer. Collected complexes were fractionated by SDS-PAGE, transferred to membranes and blotted with anti-Flag and anti-GFP antibodies as described (8) . Anti-cortactin antibodies, anti-N-terminal and 4F11, were described (25) . Monoclonal anti-myc antibody (9E10) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat polyclonal anti-GST antibody was purchased from Amersham Pharmacia Biotech; mouse monoclonal anti-GFP antibody was purchased from Zymed Laboratories (San Francisco, CA); mouse monoclonal anti-Flag antibody (M2) was purchased from Sigma Chemical. Western blots were incubated with secondary HRP-conjugated antibody and detected by using chemiluminescent reagents (ECL, Amersham).
Immunofluorescence and microscopy
Cells were plated on glass coverslips, fixed and permeabilized as described (12) . After blocking, cells were incubated with primary antibodies diluted in PBS for 1 h and secondary antibody for 45 min. To detect actin filaments, cells were stained with either 0.1 mg/ml TRITC-conjugated phalloidin (Sigma Chemical) as described (12) or Alexa Fluor 633-conjugated phalloidin per supplier recommendations (Molecular Probes Inc., Oregon, WA). Cells transfected with GFP fusion constructs were fixed 12 h after transfection, rinsed and mounted by inverting coverslips onto 5 ml of Fluoromount G (Electron Microscopy Sciences, Ft Washington, PA). Cells were examined with a LSM 510 laser scanning Zeiss confocal microscope and LSM 510 (version 4.0) digital imaging software (Zeiss, Inc., Thornwood, NY).
